TY - JOUR
T1 - New strategies in ewing sarcoma
T2 - Lost in translation?
AU - Arnaldez, Fernanda I.
AU - Helman, Lee J.
PY - 2014/6/15
Y1 - 2014/6/15
N2 - Ewing sarcoma is the second most common pediatric malignant bone tumor. Aggressive multimodality therapy has led to an improvement in outcomes, particularly in patients with localized disease. However, therapy-related toxicities are not trivial, and the prognosis for patients with relapsed and/or metastatic disease continues to be poor. In this article, we outline some of the promising therapies that have the potential to change the Ewing sarcoma therapeutic paradigm in the not-too-distant future: insulin-like growth factor receptor inhibitors, targeting of the fusion protein, epigenetic manipulation, PARP inhibitors, and immunotherapy.
AB - Ewing sarcoma is the second most common pediatric malignant bone tumor. Aggressive multimodality therapy has led to an improvement in outcomes, particularly in patients with localized disease. However, therapy-related toxicities are not trivial, and the prognosis for patients with relapsed and/or metastatic disease continues to be poor. In this article, we outline some of the promising therapies that have the potential to change the Ewing sarcoma therapeutic paradigm in the not-too-distant future: insulin-like growth factor receptor inhibitors, targeting of the fusion protein, epigenetic manipulation, PARP inhibitors, and immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84902685236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902685236&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-0633
DO - 10.1158/1078-0432.CCR-13-0633
M3 - Article
C2 - 24756371
AN - SCOPUS:84902685236
SN - 1078-0432
VL - 20
SP - 3050
EP - 3056
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -